Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477563 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
A Phase 3 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 6
- Study locations
NCT05477563: Recruiting Phase 3 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Vertex Pharmaceuticals Incorporated.
NCT05477563 is a Phase 3 study of Sickle Cell Disease and Sickle Cell Anemia that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 26 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05477563, a Phase 3 study of Sickle Cell Disease and Sickle Cell Anemia, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.
Conditions Studied
Interventions
- BIOLOGICAL CTX001
Study Locations (6)
Other
- University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology - Düsseldorf
- IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica - Rome
- King Faisal Specialist Hospital & Research Centre - Riyadh - Hematology - Al Mathar Ash Shamali
New York
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital - New York
North Carolina
- Levine Children's Hospital - Hematology - Charlotte
Tennessee
- TriStar Medical Group Children's Specialists - Pediatric Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2027-06-09 |
| Phase | Phase 3 |
What NCT05477563 shows while recruiting
NCT05477563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower).
The record links to 7 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which CTX001 is the first listed.
NCT05477563 lists 6 locations in 4 states (Other, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT05477563 about?
NCT05477563 is a clinical study titled "Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease". This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.
What is the current status of trial NCT05477563?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2022-08-02. Estimated completion is 2027-06-09.
What conditions does trial NCT05477563 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia, Thalassemia, Hematologic Diseases, Hemoglobinopathies.
What interventions are being tested in trial NCT05477563?
The interventions under investigation include: CTX001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05477563?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05477563 being conducted?
This trial has 6 study locations across New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05477563's enrollment target sits among peer trials
26 152nd of 213 higher than 62 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
RECRUITING · Phase 3
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI